Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
W Flameng, … , M Verstraete, D Collen
W Flameng, … , M Verstraete, D Collen
Published January 1, 1985
Citation Information: J Clin Invest. 1985;75(1):84-90. https://doi.org/10.1172/JCI111701.
View: Text | PDF
Research Article

Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.

  • Text
  • PDF
Abstract

Occlusive thrombus was produced by thrombin-induced coagulation in the left anterior descending coronary artery (LAD) of 16 open-chest baboons. In six control animals, occlusive thrombosis persisting over a period of 4 h as evidenced by coronary arteriography resulted in large transmural infarction (63.1 +/- 3.5% of the perfusion area). In 10 animals, tissue-type plasminogen activator obtained by recombinant DNA technology (rt-PA) was infused systemically at a rate of 1,000 IU (10 micrograms)/kg per min for 30 min after 30-80 min of coronary thrombosis. Reperfusion occurred within 30 min in nine animals. In one animal, intravenous infusion was followed by an intracoronary infusion at the same rate, which resulted in thrombolysis within 8 min. In the rt-PA group, mean duration of occlusion before reperfusion was 77 +/- 24 min. Reocclusion occurred in one animal. Recanalization resulted in an overall reduction of infarct size (37.8 +/- 5.9%, P less than 0.05 versus controls). Residual infarction was related to the duration of occlusion (r = 0.80, P less than 0.01). Reperfusion was associated with reduced reflow. Myocardial blood flow in the perfusion area of the LAD was only 70% of normal after 4 h despite perfect angiographic refilling. The infusion of rt-PA was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown, or clinically evident bleeding. It is concluded that intravenous infusion of rt-PA may recanalize thrombosed coronary vessels without inducing systemic lysis. The extent of residual infarction is closely related to the duration of coronary artery occlusion before thrombolysis.

Authors

W Flameng, F Van de Werf, J Vanhaecke, M Verstraete, D Collen

×

Total citations by year

Year: 2011 2007 2004 2001 1997 1996 1993 1992 1991 1990 1989 1988 1987 1986 1985 1984 1983 Total
Citations: 1 1 1 1 1 2 2 2 1 4 8 5 13 6 7 1 1 57
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (57)

Title and authors Publication Year
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee
Annual Reports in Medicinal Chemistry Volume 46 2011
Comprehensive Medicinal Chemistry II
E Littler, XX Zhou
Comprehensive Medicinal Chemistry II 2007
Tissue-type plasminogen activator: a historical perspective and personal account
D Collen, HR Lijnen
Journal of Thrombosis and Haemostasis 2004
Fibrinolytics and Antifibrinolytics
F Bachmann
2001
Advances in Molecular and Cell Biology
KJ Clemetson
Advances in Molecular and Cell Biology 1997
Comparative Studies of Thrombolysis with Single-Chain and Two-Chain Recombinant Tissue-Type Plasminogen Activators in Canine Coronary Thrombosis
M Yokoyama, Y Ichikawa, A Yatani, K Matsui, H Nakahara, M Kaneko, T Sakurama, S Ueshima, O Matsuo
Journal of Cardiovascular Pharmacology 1996
Comparative Studies of Thrombolysis with Single-Chain and Two-Chain Recombinant Tissue-Type Plasminogen Activators in Canine Coronary Thrombosis:
M Yokoyama, Y Ichikawa, A Yatani, K Matsui, H Nakahara, M Kaneko, T Sakurama, S Ueshima, O Matsuo
Journal of Cardiovascular Pharmacology 1996
Thrombolytic Activity of a Novel Modified Tissue-Type Plasminogen Activator, YM866, in a Canine Model of Coronary Artery Thrombosis
T Kawasaki, M Katoh, S Kaku, H Gushima, T Takenaka, Y Yui, C Kawai
The Japanese Journal of Pharmacology 1993
Thrombolysis with Intracoronary Administration of YM866, a Novel Modified Tissue-Type Plasminogen Activator, in a Canine Model of Coronary Artery Thrombosis
T Kawasaki, M Katoh, S Kaku, H Gushima, T Takenaka, Y Yui, C Kawai
The Japanese Journal of Pharmacology 1993
Mechanisms of Tissue-type Plasminogn Activator (tPA) Clearance by the Liver
M Otter, J Kuiper, TJ BERKEL, DC Rijken
Annals of the New York Academy of Sciences 1992
Recombinant tissue-type plasminogen activator ameliorates ischemic derangements induced by thrombotic occlusion in closed chest anesthetized dogs
K Egashira, K Kawai, M Nagano, A Sakuma, M Nakamura, H Tomoike
Journal of the American College of Cardiology 1992
Biotechnology of Blood
BJ Kudryk, A Bini, SF Rosebrough, TF Schaible
Biotechnology of Blood 1991
Determinants of infarct size in non-human primates
W Flameng, E Lesaffre, J Vanhaecke
Basic Research in Cardiology 1990
Serial thrombolysis-related changes after thrombolytic therapy with tPA in patients with acute myocardial infarction
CH Ho, SP Wang
Thrombosis Research 1990
A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents
JM Stassen, I Vanlinthout, HR Lijnen, D Collen
Fibrinolysis 1990
Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis
CY Liu, S Chien
1990
Coronary reperfusion by thrombolysis and early beta-adrenergic blockade in acute experimental myocardial infarction
IK Jang, FV de Werf, J Vanhaecke, H Geest
Journal of the American College of Cardiology 1989
EFFECT OF SELECTIVE ENDOPEROXIDE/THROMBOXANE A2RECEPTOR ANTAGONISM WITH SULOTROBAN ON tPA-INDUCED THROMBOLYSIS IN A RABBIT MODEL OF FEMORAL ARTERIAL THROMBOSIS
T Fujita, S Hasan, B Storer, R Shebuski
Fundamental & Clinical Pharmacology 1989
Induced clot lysis by mini-dose injection of streptokinase in non-perfused arterial segments of rabbits
RL Kolts, HS Maki, ME Kuehner, RC Roberts, RD Sautter
Thrombosis Research 1989
Thrombus age and tissue plasminogen activator mediated thrombolysis in rats
M Loren, LJ Frade, MC Torrado, JL Navarro
Thrombosis Research 1989
EFFECT OF SELECTIVE ENDOPEROXIDE/THROMBOXANE A 2 RECEPTOR ANTAGONISM WITH SULOTROBAN ON tPA-INDUCED THROMBOLYSIS IN A RABBIT MODEL OF FEMORAL ARTERIAL THROMBOSIS
T Fujita, S Hasan, B Storer, R Shebuski
Fundamental & Clinical Pharmacology 1989
A model of femoral artery thrombolysis in dogs
LR Bush, MJ Mellott, SM Kanovsky, MA Holahan, DH Patrick
Fibrinolysis 1989
Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model
JP Clozel, T Tschopp, E Luedin, P Holvoet
Circulation 1989
Tissue-Type Plasminogen Activator: A Review of its Pharmacology and Therapeutic Use as a Thrombolytic Agent
D Collen, HR Lijnen, PA Todd, KL Goa
Drugs 1989
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
AK Rao, C Pratt, A Berke, A Jaffe, I Ockene, TL Schreiber, WR Bell, G Knatterud, TL Robertson, ML Terrin
Journal of the American College of Cardiology 1988
The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model
DA Phillips, M Fisher, TW Smith, MA Davis
Annals of Neurology 1988
Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis
RJ Shebuski, BL Storer, T Fujita
Thrombosis Research 1988
Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function
DA Hart, A Rehemtulla
Comparative Biochemistry and Physiology Part B: Comparative Biochemistry 1988
Drug Concentration Monitoring Microbial Alpha-Glucosidase Inhibitors Plasminogen Activators
MB Bottorff, WE Evans, I Hillebrand, B Junge, L Müller, W Puls, DD Schmidt, E Truscheit, H Will
1988
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy
D Collen
Journal of Cellular Biochemistry 1987
A Modified Human Tissue Plasminogen Activator with Extended Half–Life In Vivo
D Lau, G Kuzma, CM Wei, DJ Livingston, N Hsiung
Bio/Technology 1987
Physiologic regulation and pathologic disorders of fibrinolysis
CW Francis, VJ Marder
Human Pathology 1987
Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
HS Mueller, AK Rao, SA Forman
Journal of the American College of Cardiology 1987
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
HD Garabedian, HK Gold, RC Leinbach, JA Johns, T Yasuda, M Kanke, D Collen
Journal of the American College of Cardiology 1987
Successful recanalisation of experimentally occluded coronary arteries in anaesthetised dogs with recombinant single-chain tissue-type Plasminogen activator (set-PA)
B Baldus, B Maaß, W Witt, P Donner
Fibrinolysis 1987
A canine model of thrombin-lnduced coronary artery thrombosis: Effects of intracoronary streptokinase on regional myocardial blood flow, contractile function, and infarct size
DC Warltier, KA Lamping, LR Pelc, GJ Gross
Journal of Pharmacological Methods 1987
Myocardial tissue salvage by coronary thrombolysis with rt-PA: Absence of occlusion/reperfusion injury
W Oliver, H Berger, CJ Frangakis
Fibrinolysis 1987
Plasminogen Activators and their Potential in Therapy
IJ Hollander, PJ Gaffney
Critical Reviews in Biotechnology 1987
Tissue Plasminogen Activator: An Evaluation of Clinical Efficacy in Acute Myocardial Infarction
SD Rogers, LB Riemersma, SD Clements
Nature Communications 1987
Coronary Thrombolysis with TissueType Plasminogen Activator
SR Bergmann, PA Ludbrook, BE Sobel
Cardiology Clinics 1987
Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol
FV de Werf, J Vanhaecke, IK Jang, W Flameng, D Collen, HD Geest
Circulation 1987
Thrombolytische Therapie des akuten Herzinfarkts
DP de Bono, ML Brochier, PG Hugenholtz, W Kübler, M Verstraete
1987
Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats
H Darius, A Yanagisawa, ME Brezinski, CE Hock, AM Lefer
Journal of the American College of Cardiology 1986
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: Effect on regional blood flow, infarct size and hemostasis
W Flameng, J Vanhaecke, DC Stump, FV de Werf, W Holmes, WA Guenzler, L Flohe, D Collen
Journal of the American College of Cardiology 1986
Turnover of human tissue plasminogen activator (tpa) in rabbits
DP Beebe, DL Aronson
Thrombosis Research 1986
Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay
A Takada, K Shizume, T Ozawa, S Takahashi, Y Takada
Thrombosis Research 1986
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
D Collen, H Bounameaux, FD Cock, HR Lijnen, M Verstraete
Circulation 1986
Tissue-Type Plasminogen Activator: Therapeutic Potential in Thrombotic Disease States
D Collen
Drugs 1986
Les activateurs du plasminogène: aspects généraux et développements récents
M Reboud-Ravaux
Biochimie 1985
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
M Verstraete, M Bory, D Collen, R Erbel, RJ Lennane, D Mathey, HR Michels, M Schartl, R Uebis, R Bernard, RW Brower, DP Bono, W Huhmann, J Lubsen, J Meyer, W Rutsch, W Schmidt, RV Essen
The Lancet 1985
Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis
EJ Topol, JE Eha, KP Brin, EP Shapiro, JL Weiss, MB Riegel, SO Gottlieb, JA Brinker
Catheterization and Cardiovascular Diagnosis 1985
DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION
M Verstraete, RW Brower, D Collen, AJ Dunning, J Lubsen, PL Michel, J Schofer, J Vanhaecke, FV de Werf, W Bleifeld, B Charbonnier, DP Bono, RJ Lennane, DG Mathey, PH Raynaud, A Vahanian, GA Kley, RV Essen
The Lancet 1985
Human tissue-type plasminogen activator: from the laboratory to the bedside
D Collen
Circulation 1985
Acute Coronary Care 1986
RM Califf, GS Wagner
1985
Clinical Application of Inhibitors of Fibrinolysis:
M Verstraete
Drugs 1985
The fibrinolytic system in man
AP Reiner, WR Bell
Critical Reviews in Oncology/Hematology 1984
New Comprehensive Biochemistry
S Yamamoto
New Comprehensive Biochemistry 1983

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts